MarketVIEW: Cytomegalovirus vaccines (CAT: VAMV014)

Background

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.

Vaccine manufacturers are currently pursuing both therapeutic (TX) and prophylatic (PX ) CMV vaccine approaches. The most advanced program is Sanofi Pasteur’s gB vaccine (+ MF59 adjuvant) where protective efficacy has been shown in post-partum women (Phase II) although development appears to be hold. Other notable approaches are Vical’s (Astellas) VCL-CB01 (ASP0113) DNA-based approach in HSCT seropositive recipients (Phase III) to be completed September 2016.

This MarketVIEW product is composed of comprehensive MS Excel-based models + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. Two forecast scenarios are included based upon the level of populations targeted, differing competitive scenarios which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.
Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Cytomegalovirus vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

**Published August 2014 (CAT No: VAMV014)**

****This product is composed of two models (.xls) and summary presentation (.pdf)

Executive summary
Key model outputs
CMV preconception vaccine: available market ($000s) to 2035 (scenario1)
CMV transplant vaccine: available market ($000s) to 2035
CMV preconception vaccine: demand (000s doses) to 2035 (scenario1)
CMV transplant vaccine: demand (000s doses) to 2035
CMV preconception vaccine: available market ($000s) to 2035 (scenario2)
CMV vaccines: revenues per company to 2035 (scenario 1)
CMV vaccines: revenues per company to 2035 (scenario 2)
CMV preconception vaccine: coverage scenarios
CMV vaccine: modelling assumptions/rationale
The role of CMV vaccine(s)
Target populations: CMV preconception vaccine
Target populations: CMV transplant vaccine
Target groups by serological risk profile
Pricing: CMV preconception vaccine
Pricing: CMV transplant vaccine
Target product profile: CMV preconception vaccine
Target product profile: CMV transplant vaccine
Key commercial model assumptions: preconception vaccine
Key commercial model assumptions: transplant vaccine
Markets included in the model
Model forecast comparisons: June 2010 v current
CMV vaccines: R&D pipeline
Competitor landscape: overview
Vical/Astellas: TransVax and CyMVectin
GSK: preconception CMV vaccine
Novartis/AlphaVax: alphavirus replicon CMV vaccine
Sanofi Pasteur: CMV gB vaccine
Merck & Co
Other vaccine candidates
Vaccine pipeline summary
Estimated launch dates: vaccines + mAbs
CMV: review of current epidemiology
Epidemiology: transplants
Epidemiology: congenital CMV infection
Appendix I: Quantifying CMV populations
Methodology: HSCTs populations (by age and serostatus)
Methodology: solid organ transplant populations (by age and serostatus)
Methodology: preconception vaccine
Other supporting data
Prevalence of CMV in the US general population
Prevalence of CMV in other general populations.
Prevalence of CMV in transplant donors and recipients
AIDS patients with CMV retinitis
Prevalence of CMV in pregnant populations
Symptomatic newborns
Management of CMV disease after solid organ transplantation
Management of CMV infection in HSCTs
Use of prophylactic/pre-emptive antivirals in HSCTs
Management of CMV retinitis in patients with AIDS
Treatment of congenital CMV in newborns
References/bibliography
About VacZine Analytics
Disclaimer

PAGES: 86 slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based)
Title sheet
Scenario definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME – HIGH
VALUE SUMMARY
VOLUME SUMMARY
Preconception vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Transplant vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Source material
Continued.....

HSCTs by serostatus
Forecast HSCTs
Forecast HSCTs
Kidney and Liver TX base
Forecast Kidney TX
Forecast liver Tx
SOT by serostatus
Populations
Back page
About VacZine Analytics
Disclaimer
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $8995.00/ GBP £5620.00 (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
# - indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
2. National Vital Statistics Reports, Volume 60, Number 1, November 3, 201.
12. ClinicalTrials.gov
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009